In this study we developed a liposome-based vaccine containing palmitoylated synthetic
long peptides (SLP) and alpha galactosylceramide (αGC) to specifically target dendritic cells …

Cancer immunotherapy requires potent tumor-specific CD8+ and CD4+ T-cell responses,
initiated by dendritic cells (DCs). Tumor antigens can be specifically targeted to DCs in vivo …

Dendritic cells (DCs) have an important role in tumor control via the induction of tumor-
specific T-cell responses and are therefore an ideal target for immunotherapy. The human …

The lipid antigen α-galactosylceramide (α-GalCer) is a potent activator of invariant natural
killer T-cells (iNKT cells) and can stimulate cytotoxic and anti-tumour immune responses …

Dendritic cells (DC) are attractive targets for cancer immunotherapy as they initiate strong
and long-lived tumour-specific T cell responses. DC can be effectively targeted in vivo with …

Dendritic cells (DCs) are antigen-presenting cells that play an important role in the body's
immune defence against cancer. Strategies using antigen-primed DCs as tumour vaccines …

Purpose: Dendritic cell (DC)-based cancer vaccines is a newly emerging and potent form of
immune therapy. As for any new technology, there are still considerable challenges that …

The most effective strategy for protection against intracellular infections such as Leishmania
is vaccination with live parasites. Use of recombinant proteins avoids the risks associated …

Lipopeptides, a form of peptide immunogens, are currently under intense investigation as
human vaccines for many infectious pathogens and cancers. However, the cellular and …

Liposomes have emerged as interesting vehicles in cancer vaccination strategies as their
composition enables the inclusion of both hydrophilic and hydrophobic antigens and …